Reprogramming the immunologically cold landscape of prostate cancer through MAOA inhibition

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Prostate cancer (PC) typically has an "immunologically cold" tumor immune microenvironment (TIME), limiting immunotherapy effectiveness.
• Stromal monoamine oxidase A (MAOA), an enzyme degrading neurotransmitters, influences the neuroendocrine system and immune responses.
• Understanding stromal factors is crucial for overcoming immune evasion in PC.

Purpose of the Study:

• To investigate the role of stromal MAOA in regulating the PC tumor immune microenvironment (TIME).
• To explore MAOA as a potential therapeutic target for enhancing PC immunotherapy.
• To analyze the WNT5A-Ca2+-NFATC1 signaling pathway's involvement in MAOA-mediated immune modulation.

Main Methods:

• Genetic and pharmacological manipulation of MAOA levels in cancer-associated fibroblasts.
• Analysis of CD8+ T cell-mediated cytotoxicity.
• Investigating the WNT5A-Ca2+-NFATC1 signaling axis.
• Evaluating the synergy of MAOA inactivation with immune checkpoint blockade therapies in preclinical models.

Main Results:

• Altering MAOA levels in cancer-associated fibroblasts reprogrammed the PC TIME.
• MAOA modulation affected CD8+ T cell cytotoxicity via the WNT5A-Ca2+-NFATC1 pathway.
• MAOA inactivation synergized with immune checkpoint blockade to inhibit prostate tumor growth.

Conclusions:

• Stromal MAOA is a critical regulator of the immune response in prostate cancer.
• Targeting MAOA offers a novel strategy to enhance immunotherapy efficacy in PC.
• MAOA represents a promising target for combination therapies to reverse prostate tumor progression.